Mean platelet volume is an important predictor of hepatitis C but not hepatitis B liver damage

Ahmet Tarik Eminler1, Mustafa Ihsan Uslan1, Talat Ayyildiz2

  • 1Department of Gastroenterology, Sakarya University, Adapazarı, Sakarya, Turkey.

Abstract

Insights

Mean platelet volume (MPV) levels are more indicative of liver damage in hepatitis C patients than in hepatitis B. This finding aids in early detection and treatment of fibrosis in hepatitis C.

Area of Science:

  • Hepatology
  • Hematology
  • Clinical Pathology

Background:

  • Mean platelet volume (MPV) is a key indicator of platelet size and reactivity.
  • MPV's association with platelet count and activity suggests its potential role in viral hepatitis.
  • Investigating MPV in hepatic histopathology can offer insights into disease progression.

Purpose of the Study:

  • To explore the relationship between hepatic histopathology in viral hepatitis (B and C) and MPV levels.
  • To assess MPV as a potential marker for platelet activity and liver damage in viral hepatitis.
  • To determine if MPV can predict histological activity and fibrosis in chronic hepatitis B and C.

Main Methods:

  • Retrospective case-control study of 205 chronic hepatitis B and 133 chronic hepatitis C patients.
  • Analysis of baseline histological (HAI, fibrosis scores via Ishak system) and clinical parameters, including MPV.
  • Patients categorized by viral hepatitis type, histological activity index, and fibrosis stage.

Main Results:

  • No significant difference in MPV was observed between activity and fibrosis groups in hepatitis B patients.
  • Hepatitis C patients showed a statistically significant difference in MPV between activity (P=0.04) and fibrosis (P=0.02) groups.
  • MPV levels correlated with advanced liver damage in hepatitis C, but not in hepatitis B.

Conclusions:

  • MPV is a more reliable predictor of advanced liver histology in hepatitis C compared to hepatitis B.
  • MPV may assist in the early detection of fibrosis in hepatitis C.
  • Utilizing MPV could facilitate timely treatment initiation for hepatitis C patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
334